Dr. Ted Henderson, one of CereScan’s consulting physicians, recently presented a webcast addressing neuroimaging in dementia, mild cognitive dementia and Parkinson’s disease. During his presentation, he discusses the merits of SPECT imaging in conjunction with the newly approved beta amyloid biomarker. Usually by the time somebody has had a clinical diagnosis of Alzheimer’s, there is already significant pathology and neuronal loss. With the use of an amyloid biomarker with PET and SPECT imaging, doctors are able to identify the disease before clinical symptoms appear. Early detection allows doctors to take advantage of treatments that have the potential to slow the progression of the disease. Below is an interesting video that was presented on NBC Nightly News about a new clinical trial that is studying potential ways to treat Alzheimer’s.